Intranasal abuse potential of an abuse-deterrent oxycodone formulation compared to oxycodone immediate release and placebo in nondependent, recreational opioid users.

CONCLUSIONS: IN administration of ELI-200 demonstrated significantly decreased effects on subjective and physiologic measures, and greater nasal irritation, compared to IN oxycodone IR. These findings, along with the PK profile of naltrexone, demonstrated that when ELI-200 capsules were ground and administered intranasally, the naltrexone component was rapidly released and conferred meaningful abuse-deterrent properties. PMID: 29308591 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/29308591?dopt=Abstract

Source: Journal of Opioid Management - January 10, 2018 Category: Addiction Tags: J Opioid Manag Source Type: research